WallStreetZenWallStreetZen

NASDAQ: DRRX
Durect Corp Stock Forecast, Predictions & Price Target

Analyst price target for DRRX

Based on 1 analyst offering 12 month price targets for Durect Corp.
Min Forecast
$5.00+437.63%
Avg Forecast
$5.00+437.63%
Max Forecast
$5.00+437.63%

Should I buy or sell DRRX stock?

Based on 1 analyst offering ratings for Durect Corp.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DRRX stock forecasts and price targets.

DRRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-01

1 of 1

Forecast return on equity

Is DRRX forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.39%

Forecast return on assets

Is DRRX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

DRRX revenue forecast

What is DRRX's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$10.1M+21.54%
Avg 2 year Forecast
$18.0M+116.8%
Avg 3 year Forecast
$23.7M+184.22%
DRRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DRRX revenue growth forecast

How is DRRX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
42.51%
Industry
8.23%
Market
9.95%
DRRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DRRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DRRX vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
DRRX$0.93$5.00+437.63%Buy
TXMD$2.22N/AN/A
QLI$0.68N/AN/A
CPIX$1.51N/AN/A
KALA$6.55$16.50+151.91%Buy

Durect Stock Forecast FAQ

Is Durect Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: DRRX) stock is to Buy DRRX stock.

Out of 1 analyst, 0 (0%) are recommending DRRX as a Strong Buy, 1 (100%) are recommending DRRX as a Buy, 0 (0%) are recommending DRRX as a Hold, 0 (0%) are recommending DRRX as a Sell, and 0 (0%) are recommending DRRX as a Strong Sell.

If you're new to stock investing, here's how to buy Durect stock.

What is DRRX's revenue growth forecast for 2024-2026?

(NASDAQ: DRRX) Durect's forecast annual revenue growth rate of 42.51% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.23%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.

Durect's revenue in 2024 is $8,321,000.On average, 3 Wall Street analysts forecast DRRX's revenue for 2024 to be $313,901,260, with the lowest DRRX revenue forecast at $226,587,481, and the highest DRRX revenue forecast at $472,108,985. On average, 1 Wall Street analysts forecast DRRX's revenue for 2025 to be $559,950,433, with the lowest DRRX revenue forecast at $559,950,433, and the highest DRRX revenue forecast at $559,950,433.

In 2026, DRRX is forecast to generate $734,081,361 in revenue, with the lowest revenue forecast at $734,081,361 and the highest revenue forecast at $734,081,361.

What is DRRX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: DRRX) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of N/A.

What is DRRX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year DRRX price target, the average DRRX price target is $5.00, with the highest DRRX stock price forecast at $5.00 and the lowest DRRX stock price forecast at $5.00.

The Wall Street analyst predicted that Durect's share price could reach $5.00 by Apr 1, 2025. The average Durect stock price prediction forecasts a potential upside of 437.63% from the current DRRX share price of $0.93.

What is DRRX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: DRRX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.